Michael Brophy, the Chief Financial Officer of Natera Inc (NTRA, Financial), has sold 1,523 shares of the company on April 23, 2024, according to a recent SEC filing. The transaction was executed at an average price of $91.38 per share, resulting in a total value of $139,113.74.
Natera Inc is a pioneer in the field of genetic testing and diagnostics, offering a range of services including prenatal testing, cancer screening, and organ health monitoring. The company's innovative approach to genetic analysis has positioned it as a leader in the rapidly evolving field of personalized medicine.
Over the past year, Michael Brophy has sold a total of 88,751 shares of Natera Inc and has not made any share purchases. This latest transaction continues a trend of insider selling at the company, with a total of 80 insider sells and no insider buys occurring over the same period.
The insider transaction history suggests a pattern of consistent share disposals by insiders, which may be of interest to current and potential investors.
In terms of valuation, Natera Inc's shares were trading at $91.38 on the day of the insider's recent sale, giving the company a market capitalization of approximately $10.99 billion. The stock's price-to-GF-Value ratio stands at 1.4, indicating that the stock is significantly overvalued according to the GF Value metric.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is calculated based on historical trading multiples, an adjustment factor for past returns and growth, and future business performance estimates provided by Morningstar analysts.
For investors monitoring insider activity, the consistent selling by the insider, along with the stock's current valuation status, may provide important context for making investment decisions regarding Natera Inc (NTRA).
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
